121 results on '"Hout, David"'
Search Results
2. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
3. A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies
4. Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy
5. 27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study
6. 101 DetermaIO (IO score) is associated with efficacy of ICI monotherapy in advanced NSCLC patients with ECOG 2
7. 59 DetermaIO (IO score) is associated with efficacy of ICI monotherapy in advanced NSCLC patients: a retrospective BC Cancer study
8. Abstract 1272: Confirmatory study of the IO Score, a tumor immune microenvironment (TIME) classifier, demonstrates efficacy in a real-world cohort of metastatic urothelial cancer (mUC) patients treated with immune checkpoint inhibitors (ICIs)
9. The 27-gene IO score is associated with molecular features and response to immune checkpoint inhibitors (ICI) in patients with gastric cancer.
10. Additional file 1 of Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
11. 466 Use of a 27-gene immuno-oncology (IO) assay to associate response to single-agent immune checkpoint inhibitor (ICI) therapy in advanced-stage NSCLC patients from a large Canadian cohort
12. A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer
13. Abstract 175: Pathway modeling to translate the 27-gene immuno-oncology algorithm into bladder cancer
14. Abstract 23: Validation of a 27-gene immuno-oncology algorithm in metastatic urothelial carcinoma treated with an immune checkpoint inhibitor
15. Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab
16. 9 Mesenchymal features of a novel 27-gene algorithm associate with canonical tumor promoting signaling pathways which may identify therapeutic options for immunotherapy resistant patients
17. Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer.
18. Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research
19. Vpu: A Multifunctional Protein that Enhances the Pathogenesis of Human Immunodeficiency Virus Type 1
20. The presence of the casein kinase II phosphorylation sites of Vpu enhances the CD4+ T cell loss caused by the simian–human immunodeficiency virus SHIVKU-lbMC33 in pig-tailed macaques
21. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype
22. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype
23. A Molecular Clone of Simian-Human Immunodeficiency Virus (ΔvpuSHIVKU-1bMC33) with a Truncated, Non-Membrane-Bound Vpu Results in Rapid CD4+ T Cell Loss and Neuro-AIDS in Pig-Tailed Macaques
24. Molecular subtypes of triple-negative breast cancer (TNBC) tumor samples obtained before and after neoadjuvant systemic therapy (NST) and relationship between immunomodulatory (IM) gene signature and intensity of tumor-infiltrating lymphocytes (TILs).
25. Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis
26. Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer
27. Association of mesenchymal subtype with the presence of immune infiltrates in squamous cancer classifier.
28. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue
29. Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients
30. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients
31. Successful treatment of hepatic oligometastases with stereotactic ablative radiotherapy and radiofrequency ablation in an anaplastic lymphoma kinase fusion‐positive lung cancer patient
32. Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease
33. Novel qPCR screen for efficient and reliable identification of RET fusion-positive non-small cell lung cancer.
34. BL1 gene expression subtype to predict outcome in serous ovarian cancers.
35. Abstract P6-08-04: Creation of a robust algorithm utilizing minimal gene sets normalized against a reference gene set to identify triple-negative breast cancer (TNBC) subtypes
36. A prospective study to compare qPCR to IHC and FISH for the detection of anaplastic lymphoma kinase (ALK) fusions in FFPE specimens from NSCLC patients (PCRTALK).
37. Spherical harmonic inductive detection coils and their use in dynamic pre-emphasis for magnetic resonance imaging
38. Routine Screening for Triple-Negative Adenocarcinoma (TNA) Lung Cancer Patients: A New Hope for a Poor-Prognosis Population
39. Anaplastic lymphoma kinase (ALK): A potential oncogenic driver in triple-negative breast cancer?
40. Abstract 1930: The unknown piece of the pie: Molecular markers in triple-negative lung cancer.
41. The Host Proteins Transportin SR2/TNPO3 and Cyclophilin A Exert Opposing Effects on HIV-1 Uncoating
42. Successful treatment of hepatic oligometastases with stereotactic ablative radiotherapy and radiofrequency ablation in an anaplastic lymphoma kinase fusion-positive lung cancer patient.
43. Abstract 2220: Insight ALK ScreenTM, a highly sensitive and specific RT-qPCR first-line screening assay for comprehensive detection of all oncogenic anaplastic lymphoma kinase (ALK) fusions: clinical validation
44. A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian–human immunodeficiency virus (SHIVKU-1bMC33) susceptible to rimantadine
45. Substitution of the transmembrane domain of Vpu in simian–human immunodeficiency virus (SHIVKU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques
46. Scrambling of the amino acids within the transmembrane domain of Vpu results in a simian-human immunodeficiency virus (SHIVTM) that is less pathogenic for pig-tailed macaques
47. Identification of a Region within the Cytoplasmic Domain of the Subtype B Vpu Protein of Human Immunodeficiency Virus Type 1 (HIV-1) That Is Responsible for Retention in the Golgi Complex and Its Absence in the Vpu Protein from a Subtype C HIV-1
48. Vpu-mediated CD4 down-regulation and degradation is conserved among highly divergent SIVcpz strains
49. Fusion of the upstream vpu sequences to the env of simian human immunodeficiency virus (SHIVKU-1bMC33) results in the synthesis of two envelope precursor proteins, increased numbers of virus particles associated with the cell surface and is pathogenic for pig-tailed macaques
50. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.